Hans Tesch
Impact in
- Cancer Research top 0.2%
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
- Oncology top 0.2%
- HER2/EGFR in Cancer Research
- Cancer Cells and Metastasis
- Cancer Immunotherapy and Biomarkers
Papers in
- Oncology 167
- HER2/EGFR in Cancer Research 57
- Cancer Treatment and Pharmacology 33
-
- Breast Cancer Treatment Studies 89
- Co-authors
- Volker Diehl (94 shared papers)Dieter Kube (22 shared papers)Heribert Bohlen (26 shared papers)Sibylle Loibl (38 shared papers)Jens Huober (35 shared papers)Gϋnter von Minckwitz (23 shared papers)Peter Andreas Fasching (45 shared papers)Jeremy G. Franklin (12 shared papers)
- Journals
- Annals of Oncology (40 papers)European Journal of Cancer (23 papers)Journal of Clinical Oncology (15 papers)Blood (14 papers)Breast Cancer Research and Treatment (9 papers)
- Partner nations
- GermanyUnited StatesSwitzerland
In The Last Decade
Hans Tesch
368 papers receiving 15.7k citations
Hans Tesch's Hit Papers
Peers
Comparison fields: 5 of 143
- Cancer Research 4.4k
- Oncology 7.6k
- Pathology and Forensic Medicine 3.3k
- Immunology 2.1k
- Genetics 1.1k
Countries citing papers authored by Hans Tesch
This map shows the geographic impact of Hans Tesch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hans Tesch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hans Tesch more than expected).
Fields of papers citing papers by Hans Tesch
This network shows the impact of papers produced by Hans Tesch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hans Tesch. The network helps show where Hans Tesch may publish in the future.
Co-authors
The 25 scholars most cited alongside Hans Tesch, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 393 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Positive and Triple-Negative Primary Breast Cancers Hit paper breakdown → | 2014 | 868 |
| 2 | Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial Hit paper breakdown → | 2014 | 799 |
| 3 | Standard and Increased-Dose BEACOPP Chemotherapy Compared with COPP-ABVD for Advanced Hodgkin's Disease Hit paper breakdown → | 2003 | 638 |
| 4 | A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study Hit paper breakdown → | 2019 | 562 |
| 5 | Circulating Tumor Cells Predict Survival in Early Average-to-High Risk Breast Cancer Patients Hit paper breakdown → | 2014 | 515 |
| 6 | Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial Hit paper breakdown → | 2017 | 461 |
| 7 | 2010 | 450 | |
| 8 | 2010 | 430 | |
| 9 | Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer Hit paper breakdown → | 2012 | 429 |
| 10 | Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials Hit paper breakdown → | 2021 | 409 |
| 11 | Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial Hit paper breakdown → | 2012 | 359 |
| 12 | 1997 | 331 | |
| 13 | 2010 | 240 | |
| 14 | 1995 | 199 | |
| 15 | 2001 | 196 | |
| 16 | 2013 | 195 | |
| 17 | 2000 | 189 | |
| 18 | 2007 | 187 | |
| 19 | 2000 | 183 | |
| 20 | 2010 | 180 |
About Hans Tesch
Hans Tesch is a scholar working on Oncology, Cancer Research, Pathology and Forensic Medicine, Pulmonary and Respiratory Medicine and Genetics, having authored 393 papers that have together received 16.3k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (89 papers), Lymphoma Diagnosis and Treatment (74 papers), Advanced Breast Cancer Therapies (66 papers), HER2/EGFR in Cancer Research (57 papers), Monoclonal and Polyclonal Antibodies Research (39 papers), Chronic Lymphocytic Leukemia Research (34 papers), Cancer Treatment and Pharmacology (33 papers) and Lung Cancer Treatments and Mutations (25 papers). The work is most often cited by research in Cancer Research (4.4k citations), Oncology (7.6k citations), Pathology and Forensic Medicine (3.3k citations), Immunology (2.1k citations) and Genetics (1.1k citations). Hans Tesch has collaborated with scholars based in Germany, United States and Switzerland. Frequent co-authors include Volker Diehl, Dieter Kube, Heribert Bohlen, Sibylle Loibl, Jens Huober, Gϋnter von Minckwitz, Peter Andreas Fasching, Jeremy G. Franklin, Michael Untch and Holger Eidtmann. Their work appears in journals such as Annals of Oncology, European Journal of Cancer, Journal of Clinical Oncology, Blood and Breast Cancer Research and Treatment.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.